CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,268 enrolled
Drug / intervention
rizatriptan benzoate +3 moredrug
Likely dose
rizatriptan benzoate 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00898677
NCT00898677Phase 3Completed

A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Single Oral Doses of MK0462 5 mg, MK0462 10 mg, and Sumatriptan 100 mg for Acute Treatment of Migraine

Organon and Co·interventional·Posted May 12, 2009·Updated Feb 3, 2022

In Brief

A Phase 3 clinical trial evaluating rizatriptan benzoate, Comparator: sumatriptan, and 1 other intervention for Migraine Headache. Completed, enrolled 1,268 participants.

Detailed Summary

A study to compare rizatriptan 10 mg verse sumatriptan 100 mg in the treatment of migraine attacks and duration of relief provided. This study will also provide additional efficacy data on rizatriptan 5 mg and 10 mg for the treatment of migraine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 12, 2009
Enrollment StartSep 1, 1995
Primary CompletionMay 1, 1996
Study CompletionSep 1, 1996
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.1 years ago

Interventions

rizatriptan benzoatedrug

single dose administration of 5mg rizatriptan (by Mouth) p.o.

rizatriptan benzoatedrug

single dose administration of 10 mg rizatriptan p.o.

Comparator: sumatriptandrug

single dose administration of sumatriptan 100 p.o.

Comparator: Placebodrug

placebo to rizatriptan